Novartis Counts On Adherence, Access And Affordability To Ensure Inclisiran’s US Success
Drug Maker Refiles PCSK9 Inhibitor Leqvio After December CRL
Novartis is aiming for adherence, access and affordability to ensure Leqvio's success in the US • Source: Shutterstock